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Major depressive disorder (MDD) is a common complex disorder with a partly genetic etiology.
We conducted a genome-wide association study of the MDD2000þ sample (2431 cases, 3673
screened controls and >1M imputed single-nucleotide polymorphisms (SNPs)). No SNPs
achieved genome-wide significance either in the MDD2000þ study, or in meta-analysis with
two other studies totaling 5763 cases and 6901 controls. These results imply that common
variants of intermediate or large effect do not have main effects in the genetic architecture of
MDD. Suggestive but notable results were (a) gene-based tests suggesting roles for adenylate
cyclase 3 (ADCY3, 2p23.3) and galanin (GAL, 11q13.3); published functional evidence relates
both of these to MDD and serotonergic signaling; (b) support for the bipolar disorder risk
variant SNP rs1006737 in CACNA1C (P=0.020, odds ratio=1.10); and (c) lack of support
for rs2251219, a SNP identified in a meta-analysis of affective disorder studies (P=0.51).
We estimate that sample sizes 1.8- to 2.4-fold greater are needed for association studies of
MDD compared with those for schizophrenia to detect variants that explain the same
proportion of total variance in liability. Larger study cohorts characterized for genetic and
environmental risk factors accumulated prospectively are likely to be needed to dissect more
fully the etiology of MDD.
Molecular Psychiatry (2012) 17, 36–48; doi:10.1038/mp.2010.109; published online 2 November 2010
Keywords: major depressive disorder; depression; genome-wide association study; CACNA1C;
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Introduction
Major depressive disorder (MDD) is a common and
debilitating disorder with pervasive impact on the
quality of life for both sufferers and their families.
Lifetime prevalence is estimated to be B15%,
1,2 and
is consistently estimated to be twice as common in
women as men.
3,4 MDD is associated with high
morbidity, reflected in estimates of burden of disease
and years lost in productivity,
1,5 and excess mortality
from suicide
6 and other causes. Our understanding
of the etiology of MDD remains fragmented, despite
wide-ranging research, but is the key to effective
prevention and treatment.
MDD is familial, with heritability estimated to be
0.37 (95% confidence interval (CI) 0.31–0.42) and
both early age of onset and recurrence of depression
are associated with higher familial aggregation.
7,8
This implied genetic etiology has motivated studies
designed to identify specific genetic variants asso-
ciated with MDD. Results from genome-wide linkage,
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9 and candidate gene
association studies
10 have shown little consistency
and hopes for new progress have spurred on a gene-
ration of genome-wide association studies (GWAS).
Five GWAS for MDD have been published to date,
11–15
each using control samples screened negative for
MDD. None of these studies has identified variants
that achieve genome-wide significance. Taken to-
gether, the results of these studies imply that specific
genetic variants individually make very small con-
tributions to the etiology of MDD. In this study, we
present the largest GWAS for MDD to date, the
MDD2000þ study comprising 2431 cases and 3673
screened controls. We compare our results with
reports of the other published MDD GWAS and
present a formal meta-analysis of our results with
the two other largest studies (5763 cases and 6901
controls).
Materials and methods
Overview
The MDD2000þ project comprises a total of 2431
cases with MDD and 3673 screened controls from
different sources and genotyped on different plat-
forms (Tables 1 and 2). Samples were provided by the
Queensland Institute of Medical Research (QIMR,
Australia), The Netherlands Study of Anxiety and
Depression (NESDA), The Netherlands Twin Registry
(NTR), the University of Edinburgh (UK), and the
Molecular Genetics of Schizophrenia study (controls
only, US). Genotyping was conducted on different
Illumina and Affymetrix platforms and because the
overlap in genotyped single-nucleotide polymorph-
isms (SNPs) is limited, association analysis is based
on a set of >1M imputed SNPs. The number of SNPs
for each analysis set (Table 1), represents genotyped
SNPs surviving all quality control (QC) criteria that
were used for imputation.
Subject recruitment
QIMR. Study participants were adult twins and
their families recruited through the Australian Twin
Registry (http://www.twins.org.au). Only unrelated
individuals were included in MDD2000þ. All parti-
cipants provided written informed consent under
study protocols approved by the QIMR Human
Research Ethics Committee. MDD cases were
identified through psychiatric questionnaires, either
the shortened Composite International Diagnostic
Interview
16 or the SSAGA-OZ interview instrument
(a version of the Semi-Structured Assessment for
the Genetics of Alcoholism
17 modified for use in
Australia), a comprehensive psychiatric interview
designed to assess MDD and other psychiatric
disorders
17 according to DSM-IIIR
18 and DSM-IV
19
criteria. Structured interviews were administered by
trained telephone interviewers, closely supervised by
a clinical psychologist. Briefly, from 1988 to 1990,
study participants were mailed an extensive health and
lifestyle questionnaire, which included the shor-
tened revised Eysenck personality questionnaire.
20
Sum scores of 12 item responses in each personality
domain resulted in quantitative scores for neuroticism.
Between 1992–2000, an unselected subset of these
participants were interviewed by telephone using the
SSAGA-OZ.
21 Over the period 1996–9 sibling pairs that
were either concordant or discordant for extreme
neuroticism scores (one sibling in the top or bottom
decile, the other sibling in the top or bottom quintile)
were recruited to complete the Composite International
Diagnostic Interview, which provides DSM-IV
19
lifetime diagnoses of MDD.
22 Finally, some study
participants completed the SSAGA-OZ telephone
questionnaire in 2003–2007 as part of alcohol and
nicotine dependence studies (the nicotine addiction
genetics and Inter-related Project Grant studies
d e s c r i b e di nT a b l e2o fH a n s e l let al.
23). The Inter-
related Project Grant/nicotine addiction genetics
studies captured 28% of families who had already
participated in earlier studies ascertaining those with
either (a) large sibship size or containing a proband
with either (b) nicotine dependence or (c) alcohol
dependence. For this study, all cases met DSM-IV
lifetime criteria for MDD. Screening items for mania
were not consistent across interviews and screening
items for psychosis were not included; the ability
to assess accurately these less common criteria is
difficult in large-scale community settings. Therefore,
it is possible that a small number of individuals with a
primary diagnosis of bipolar disorder or schizophrenia
are included in the case group. If multiple cases were
present within families then one case was selected
in the following order of preference: age of onset
<31 years, multiple episodes of depression, co-morbid
anxiety disorders and high neuroticism score.
Unrelated controls were selected as genotyped
individuals from families in which no individuals
qualified for diagnoses of MDD or anxiety disorders. If
multiple controls were available from a family, the
individual with the lowest neuroticism score was
preferentially selected, otherwise an individual was
selected at random.
NESDA and NTR. Additional MDD cases were
selected from two parallel studies, NESDA
(http://www.nesda.nl) and NTR (http://www.
tweelingenregister.org); NTR also provided screened
controls. These samples do not overlap with those
included in a prior MDD GWAS
12 but are drawn from
the same parent studies (although a small number of
related individuals are included, see meta-analysis
section below). Details of the data collection methods
are described elsewhere.
9 Similar inclusion and
exclusion criteria were used to select MDD cases
from both the NESDA and NTR studies. Inclusion
criteria were a lifetime diagnosis of DSM-IV MDD
as determined by the Composite International
Diagnostic Interview,
16 age 18–65 years, and self-
reported western European ancestry. Those not fluent
in Dutch or with a primary diagnosis of schizophrenia
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Molecular Psychiatryor schizoaffective disorder, obsessive–compulsive
disorder, bipolar disorder or severe substance use or
dependence were excluded. All subjects provided
written informed consent after study approval by the
appropriate Institutional Review Boards.
University of Edinburgh. MDD cases were recruited
through in- and out-patient services of psychiatric
hospitals in Scotland and were tertiary referrals from
primary care. All patients were interviewed by an
experienced psychiatrist using the Schedule for
Affective Disorders and Schizophrenia-Lifetime,
24
supplemented by hospital case note review and
information from informants. Final determination of
MDD as the primary DSM-IV diagnosis was made by
consensus of two psychiatrists. All cases had a lifetime
history of recurrent MDD and IQ >70. The study was
approved by the Central Office of Research Ethics
Committees in Scotland and all subjects gave informed
written consent for the collection of DNA samples for
use in genetic studies.
Molecular Genetics of Schizophrenia controls. Briefly,
random digit dialing was used to achieve a
representative sample of individuals from the United
States. Participants completed an online questionnaire
including the short form Composite International
Diagnostic Interview, supplemented by questions
about schizophrenia, psychosis and bipolar disorder.
Controls were required to never have met criteria for
MDD. All subjects provided informed consent. These
controls have been used in GWAS for multiple
psychiatric disorders including MDD.
13,14
Genotyping and QC
Full details are given in the Supplementary File 1. All
analysis sets were put through a common QC pipeline
based on that used by the Psychiatric GWAS Con-
sortium.
25 SNPs were removed based on the following
criteria: minor allele frequency (MAF) <0.01, Hardy–
Weinberg equilibrium test P<1 10
 6 in controls,
missingness >0.01 or 0.02, missingness difference
between cases and controls of 0.01 or 0.02, difference
in frequency with HapMap of 0.07 or 0.15 (more
stringent thresholds were applied when cases and
controls were not genotyped concurrently, and were
chosen to balance SNPs lost versus genomic control
inflation factors). Samples were removed with miss-
ingness >0.02, if related to other samples or if
identified as European ancestry outliers. Imputation
was conducted in four analysis sets (I317, I370, I610,
A6.0) in batches of B300 mixed cases and controls to
a common set of SNPs present in HapMap3 CEU/TSI,
consisting of 410 haplotypes, using Beagle 3.04.
26,27
Statistical analyses
Association analysis was conducted on 2431 MDD
cases and 3673 screened controls using allelic
dosages for imputed SNPs passing QC. The test of
association was logistic regression, including the
first three ancestry principal components (PC) and
analysis set as covariates. The INFO score (ratio
of observed to expected dosage variance), a measure
of the quality of imputation of SNPs was used to
interpret results. A second association analysis was
conducted restricting cases to those with recurrent
early onset MDD (REO, age of MDD onset <31 years
with multiple episodes of MDD). Separate analyses
were conducted by sex, as different prevalences of
MDD between males and females could imply
existence of sex-specific genetic risk variants.
Statistical power
Detailed power calculations are provided in the
Supplementary File 1. The MDD2000þ sample
affords >90% power to detect an associated variant
with MAF 0.36 and genotype relative risk (GRR) 1.33
(the median values across all published complex
disease/trait GWAS, with P<5 10
 8).
28
Comparison of association results with other studies
including meta-analysis
We compared our results with those published for
other GWAS of MDD. In particular, we conducted a
formal genome-wide meta-analysis for autosomal
SNPs from MDD2000þ, GAIN–MDD
12 and UK
15
studies (that is, the three largest MDD GWAS). The
GAIN–MDD sample, after removing individuals
related to Dutch cases or controls of MDD2000þ,
comprised 1696 MDD cases and 1634 screened
controls and the UK sample comprised 1636 MDD
cases and 1594 screened controls. Meta-analysis
29 on
the logistic regression results from each study,
restricting the imputed SNPs to those with INFO
scores between 0.8 and 1.1.
Gene-based tests
To determine whether any genes harbored an excess
of SNPs with small P-values, we undertook genome-
wide gene-based tests which account for both gene
length and linkage disequilibrium between SNPs
using VEGAS.
30 SNPs were allocated to one or more
autosomal genes using gene boundaries ±50kb. We
investigated 183 candidate genes for MDD.
12–15,31
Results
Of 1,251,157 imputed SNPs, 1,079,979 (86%) had
MAF>0.01 and INFO>0.8. The quantile–quantile
plots of the observed versus expected  log(P) from
the four (total, male, female and REO) association
analyses are presented in Figure 1 and Supplemen-
tary File 1. The genomic control l (the median w
2
association statistic divided by the median expected
under the null) shows no evidence for inflation of the
test statistics. For example, for the full analysis,
l=1.05 (and standardized to a sample size of 1000,
l1000=1.02). There were no genome-wide significant
results with P<5 10
 8. The Manhattan plot of
association P-values for all subjects is presented
in the Supplementary File 1 and Table 3 shows
associations with <1 10
 5 in any analysis.
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Molecular PsychiatryRegional association and forest plots are provided in
Supplementary File 2. SNPs associated with P<0.001
in any analysis are provided in Supplementary File 3.
Comparison of association results with other studies
including meta-analysis
We compared the MDD2000þ results with other
published studies. Muglia et al.
11 listed 27 SNPs with
P<1 10
 5; 25 SNPs overlapped with our analysis
but none had P<0.05 and association with the same
allele. Of the top 200 SNPs in one or both of their
study samples, B90% were analysed in our study but
B5% had P<0.05, consistent with chance expecta-
tions. As the MDD2000þ controls were also used
in GenRed
13 and STARD,
14 we did not make formal
comparisons of our results, but we note that B5%
of their top SNPs (P<1 10
 5) had P<0.05 in
MDD2000þ. The SNP rs2251219 identified as a mood
disorder risk factor in a GWAS meta-analysis (three
bipolar studies plus the GAIN–MDD study)
32 but was
not associated in MDD2000þ (P=0.51, MAF=0.40,
odds ratio (OR)=0.97, 95% CI 0.90–1.05). PCLO was
the top finding in the GAIN–MDD study,
12 replicated
in Australian (QIMR)
12 and Dutch
33 samples, but we
found no evidence for association with PCLO variants
(for example, P=0.51 for rs2522833), despite partial
overlap (562 cases and 264 controls) in the QIMR
samples used here and in the original replication
sample (see Supplementary File 1 for details). Meta-
analysis results of the three largest MDD GWAS—
427362 SNPs in MDD2000þ, GAIN–MDD and the UK
studies—yielded l1000=1.01 (Figure 1iii). In all, 19
SNPs gave P<5 10
 5 compared with B21 expected
under the null hypothesis (ignoring linkage disequili-
brium) and are listed in the Supplementary File 1.
Gene-based tests
MDD2000þ SNPs mapped to 18454 genes. We list all
genes with P<1 10
 4 and all lie within linkage
regions identified in the SLEP
34 database of research
findings for psychiatric disorders. Gene ontology
annotations and names are provided for these genes
(Table 4). Three are plausible candidate genes for
MDD (GAL, ADCY3, PDK4) and others have a role in
ion binding (ZDHHC19, ZNF83). None of the genes
listed in Table 4 shows any evidence for association
in the gene-based test applied to GAIN–MDD or the
UK MDD GWAS results, although association at
P<0.001 is retained for GAL in the gene-based test
applied to the meta-analysis results.
Of the 183 candidate genes investigated in other
GWAS for MDD, we could test for association with
180 (Supplementary File 4). None were associated
with P<0.00028 (0.05/180). The six most associated
were IL10, OPRM1, HTT, HTR1B, GRIN1 and CAC-
NA1C. Of these, OPRM1 was reported to have P<0.05
in the GAIN–MDD gene-based test and CACNA1C was
top ranked in the GenRed
13 study; the other studies
all used a gene test based on best single associated
SNP corrected for gene length. In this study,
CACNA1C ranked 808 out of 18454 (4th percentile).
Our top associated SNP in CACNA1C is rs98545
(P=0.0019, OR=0.83, MAF=0.15) which is 387kb
from, and in near linkage equilibrium (r
2=0.06) with,
rs1006737 (P=0.020, OR=1.10, MAF=0.35), the SNP
first identified in genome-wide association studies of
bipolar disorder;
35 an interaction between these SNPs
was not significant (P=0.21). The 3rd ranked of the
candidate genes (Huntingtin, HTT) was included in
the candidate list because mood disorders are char-
acteristic of presymptomatic carriers of the Hunting-
ton’s disease trinucleotide repeat polymorphisms.
31
HTT ranked in the top 0.7% of all genes; the SNP
showing highest individual association within the
gene is rs363099 (also known as rs4690074, P=4.7
E 04, OR=0.86, MAF=0.31) located in exon 29,
85kb from the exon 1 CAG repeat.
Discussion
Study results
The MDD2000þ study is the largest GWAS for MDD
reported to date, comprising 2431 cases with MDD
and 3673 screened controls. Our analysis was of
>1M SNPs but none achieved genome-wide signifi-
cance. Indeed, the quantile–quantile plots (Figure 1)
show that the distribution of observed associations
closely follows that expected under the null hypoth-
esis. These results are consistent with other GWAS
of MDD.
11–15 Furthermore, comparison of our results
with these other studies including formal meta-
analysis of results from MDD2000þ and the next
two largest studies
12,15 (a total of 5763 cases and 6901
Figure 1 Quantile–quantile plots for the association analyses of (i) all cases and controls and (ii) recurrent early onset (iii)
meta-analysis.
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between studies.
To determine whether any genes harbored an excess
of low-associated variants, we undertook gene-based
tests which account for both gene length and linkage
disequilibrium between SNPs. Our top associated
genes were not replicated in the gene-based test
when applied to the GAIN–MDD or UK MDD
results, although some genes retained low association
P-values when applied to the meta-analysis results
(Table 4). Despite this there are some suggestive
results worthy of note. Among the top ranked genes
is GAL, which encodes the neuropeptide galanin,
proposed by Weiss et al.
36 as having an important role
in MDD. Their hypothesis, based on animal models is
that GAL released in the ventral tegmentum inhibits
the activity of dopaminergic cells resulting in de-
creased motor activity and anhedonia. GAL is a
regulator of brain serotonin and 5-HT1A receptor-
mediated transmission,
37 agonists of GAL receptors
have been proposed as potential drug targets
for MDD.
38 GAL also has an important role in the
hippocampal processing of cognition.
39 Our most
associated SNP in GAL (rs2156464, P=2.7 10
 5,
OR=1.24, CI=1.12–1.37, MAF=0.19) lies in the same
haplotype block as an association reported for panic
disorder.
40 Another top ranked gene (ADCY3) encodes
the enzyme adenylate cyclase 3 that catalyses
synthesis of cyclic adenosine monophosphate,
the association underpinned by SNP rs2384061
(P=6.3 10
 6, OR=1.20, CI=1.11–1.29, MAF=0.42,
Table 3). ADCY3 is an plausible candidate gene
because depressed patients display reduction in
platelet ADCY activity.
41 Perhaps most interesting
is that ADCY and GAL activity are inter-related
42
and ADCY3 binds CACNA1C (calcium channel,
voltage dependent, L type, a-1C subunit).
43 A SNP
(rs1006737, intron 3) within the gene CACNA1C is
associated with bipolar disorder
44 schizophrenia
and MDD.
45 In this study, CACNA1C ranked in the
top 4% of genes and we replicated the association
with rs1006737 (P=0.020, OR=1.10, CI=1.01–1.19,
MAF=0.34), but the top associated SNP in CACNA1C
was rs98545 (P=0.0019, OR=0.83, CI 0.75–0.94,
MAF=0.15, intron 29). rs98545 lies 387kb from
rs1006737; they are in near linkage equilibrium
(r
2=0.06) and in our data their effects are additive
in a logistic regression. Neither rs1006737 nor
rs98545 were genotyped in the UK MDD or GAIN–
MDD studies; imputation of GAIN–MDD genotypes
showed weak association with rs1006737 (P=0.070,
OR=1.10, CI=0.99–1.21, MAF=0.32) but not with
rs98545 (P=0.52). We cannot exclude that the
association of rs98545 has occurred by chance in
our sample. Regional association plots for ADCY3,
GAL and CACNA1C can be found in Supplementary
File 2.
Despite the large sample size of MDD2000þ,a
number of limitations may reduce the realized power
for detection of association. First, our study combines
data sets genotyped on different primary platforms,
and the power of our sample will vary between SNPs
depending on the linkage disequilibrium structure
between genotyped and imputed SNPs. Second, some
of our cases and controls were genotyped separately
because of economic constraints. We were fortunate
that we had >300 QIMR cases genotyped on both the
Affymetrix and Illumina platforms, which we used
extensively for QC. Third, when combining cases and
controls genotyped as separate sets, it was necessary
to impose more stringent QC constraints than for
cases and controls genotyped on the same platform.
These constraints were successful in removing arte-
factual differences between the case–control sets, but
could also have eliminated true associations. Fourth,
in MDD2000þ with the aim of maximizing sample
size we have combined the clinical cases from the
University of Edinburgh cohort with the community
samples from QIMR and NTR. The extent to which
this is important depends on the unknown genetic
etiology of MDD. Lastly, 26% of both cases and
controls contributed by the QIMR sample (which
makes the largest contribution in this study) were
from families ascertained on the basis of a sibling
with nicotine dependence, as reflected by the high
proportion of smokers in the QIMR samples. Smoking
is associated with depression and if some genes
are involved in smoking behavior and MDD, then the
power to detect genetic variants for MDD may be
reduced.
Implications
Our analysis and meta-analysis represent the largest
and most powerful investigation into the genetic
architecture of MDD to date. The lack of clear-cut
evidence for association allows us to exclude genetic
main effects that are common (MAF>0.1) with
moderate to strong effect sizes (GRR>1.4). As noted
earlier, the MDD2000þ sample alone possessed
>90% power to detect the median MAF (0.36) and
GRR (1.33) of GWAS associations published to date
with P<5 10
 8. Moreover, as we would expect
to detect >20% of variants with OR 1.2 and MAF
0.2–0.7 (Supplementary File 1), and having detected
none that are genome-wide significant, we can
probably draw an even more stringent boundary on
the risk allele architecture under a main effect model.
These results are informative for researchers planning
association studies of MDD.
These results are unsurprising in the light of results
for a range of complex genetic disorders published
since this study was conceived in 2007.
46 Results
from GWAS of psychiatric disorders
47 have, on the
whole, yielded replicated associations only for low
prevalence/high heritability disorders, that is, autism,
bipolar disorder and schizophrenia, with tobacco
dependence being the exception.
48 As a high
prevalence/low heritability disorder, the challenge
for MDD was always going to be harder. From Yang
et al.,
49 we estimate that sample sizes 2.4-fold greater
are needed for GWAS of MDD (prevalence 0.15)
compared with schizophrenia (prevalence 0.007) to
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of phenotypic variance to liability of these disor-
ders (Supplementary File 1). This result reflects the
smaller mean difference in phenotypic liability
between cases and controls for MDD compared with
schizophrenia. Hospital-based MDD cohorts may
represent a more extreme phenotype, with lower
prevalence and higher heritability.
50 Using a preva-
lence for such clinical samples to be 0.06 (the average
across sexes)
51 still requires a sample size B1.8 times
greater for a case–control study of MDD compared
with one for schizophrenia.
Further, for main effect models, as the heritability
on the liability scale (h
2) is a function of the number
of variants (n), their frequencies (qi) and their effect
sizes (ai),
h2 ¼ 2
X n
i¼1
qið1   qiÞa2
i ð1Þ
(with total variance of liability of 1), then the lower
heritability of MDD (B0.37, although this may be
higher in clinical samples)
51 compared to schizo-
phrenia (B0.81), must be explained by fewer risk
alleles, lower risk allele frequencies and/or smaller
effect sizes. It seems most plausible that MDD might
have smaller effect sizes compared with schizophre-
nia (except in the unlikely event that the number
of loci for MDD is substantially fewer than for
schizophrenia). We estimate that sample sizes 4–5
times those needed for schizophrenia studies may
be needed for MDD to detect variants that explain
an equal proportion of the known genetic variance
(Supplementary File 1).
Study designs
It is clear that larger sample sizes are needed to
achieve the power required to detect common
variants of smaller effect, and that larger sample sizes
will be needed for MDD compared with less prevalent
but more heritable disorders. The prize is major: any
replicated hit provides a priceless window into the
etiology of this idiopathic disorder. However, alter-
native and complementary strategies are possible,
particularly those that consider a broader range
of genetic models and relax further assumptions of
etiological homogeneity.
First, recognizing that effect size is the average
effect of a variant across all genetic and environ-
mental backgrounds,
52 it may be possible to forgo
larger sample sizes to concentrate on more homo-
genous subsets in which larger effect sizes may be
detectable. There has been much debate about the
genetic heterogeneity of MDD. Some genetic hetero-
geneity is consistent with the polygenic model; each
affected individual could potentially harbor a differ-
ent combination of risk variants which could imply
a spectrum of phenotypic symptoms, with those
presenting similar symptom profiles carrying more
similar profiles of risk alleles, consistent with
symptom sharing of closely related individuals.
53
For this reason, most GWAS for MDD have prioritized
genotyping of the less prevalent and more heritable
recurrent early onset MDD, but even so genome-wide
significant associations have been elusive. Stratifica-
tion by sex has also not yielded consistent results.
Other possibilities certainly exist but phenotypes may
be unavailable (for example, accurate delineation
of typical versus atypical MDD)
54 or prohibitively
expensive (for example, magnetic resonance imaging).
Use of quantitative scores of severity and reliability
may be the best strategy to balance sample size with
phenotype definition,
55 as MDD symptom profiles are
consistent with a quantitative rather than dichoto-
mous liability.
56
Second, in addition to achieving a more homo-
genous genetic background, larger estimated effect
sizes may come from selecting more homogenous
environmental backgrounds. The low heritability
of liability for MDD implies an important role for
environmental risk factors. Although genoty-
pe environment interaction cannot explain the
so-called ‘missing heritability’,
52 it can contribute to
small effect sizes. Although genotype environment
studies are conceptually attractive, the lessons
learned from the most studied genotype environ-
ment hypothesis for MDD (5HTTLPR and stressful life
event) are sobering.
57 However, this broad conclusion
has been challenged
58,59 with Uher and McGuffin
58
arguing that replication has been achieved when
stressful life event were recorded objectively, tempo-
rally and before the onset to MDD. More mileage
might be gained by considering MDD in the context of
more clearly defined exposures, such as pregnancy,
in which women with perinatal and post-partum
MDD have been exposed to a similar event.
Whichever way we look at it, and whether risk
variants are common or rare, it seems that the
challenge for MDD will be much harder than for the
less prevalent more heritable psychiatric disorders.
Larger samples are required whether we attempt to
identify associated variants with small effect across
average backgrounds or attempt to enhance detectable
effects sizes by selection of homogeneity of genetic or
environmental background. In the long-term, a greater
understanding of the etiology of MDD will require
large prospective, longitudinal, uniformly and
broadly phenotyped and genotyped cohorts that allow
the joint dissection of the genetic and environmental
factors underlying MDD.
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